Clinical Trials Arena on MSN
ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months
ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy ...
Zacks Investment Research on MSN
ImmunityBio shares surge on updated durable lymphoma study results
Shares of ImmunityBio IBRX surged 39.8% on Friday and added a further 9.4% in after-hours trading after the company reported ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
Despite 700% net product revenue growth to $113 million, ImmunityBio's high debt load and unprofitability remain significant ...
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.
Shares surged 30% Thursday after reporting 700% Anktiva revenue growth and securing Saudi FDA approvals for lung and bladder ...
Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients. The stock closed the ...
ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source of BCG.” Specifically, the company will now be able to provide this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback